Clinical Trials
Prostate
Recruiting
ANZadapt
ANZUP 2101
NSW | VIC | QLD | SA | WA
Phase II randomised controlled trial of patient-specific adaptive versus continuous Abiraterone or eNZalutamide in metastatic castration-resistant prostate cancer
Bladder
In Follow-up
BCG+MM
ANZUP 1301
NSW | VIC | QLD | WA | UK
Adding mitomycin to BCG as adjuvant intravesical therapy for high-risk, non–muscle-invasive bladder cancer: a randomised phase III trial
Testicular
Recruiting
CLIMATE
ANZUP1906
NSW | VIC | QLD | NZ
Assessing the Clinical utility of miR-371a-3p as a marker of residual disease in Clinical Stage 1 Testicular Germ Cell Tumour, following orchidectomy.
Prostate
In Follow-up
DASL-HiCaP
ANZUP 1801
NSW | VIC | QLD | SA | TAS | WA | NZ | Ireland | Canada | USA
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
Prostate
In Follow-up
ENZA-p
ANZUP 1901
NSW | VIC | QLD | SA | WA
A randomised phase II trial using PSMA as a therapeutic agent and prognostic indicator in people with metastatic castration-resistant prostate cancer treated with enzalutamide.
Prostate
In Follow-up
ENZAMET
ANZUP 1304
NSW | VIC | QLD | NT | SA | TAS | WA | NZ | UK | Ireland | Canada | USA
Enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: a randomised phase III trial
Prostate
In Follow-up
ENZARAD
ANZUP 1303
NSW | VIC | QLD | SA | TAS | WA | NZ | UK | Ireland | Belgium | USA | Spain | Austria | Slovenia
Enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer: a randomised phase III trial
Prostate
In Follow-up
EVOLUTION
ANZUP 2001
NSW | VIC | SA | WA
Phase II Study of Radionuclide 177Lu-PSMA Therapy versus 177Lu-PSMA in Combination with Ipilimumab and Nivolumab for people with Metastatic Castration Resistant Prostate Cancer
Prostate
Recruiting
GenI-AIRSPACE
ANZUP2102
VIC
Evaluating the effect of genomically informed treatment decision-making on long-term oncological outcomes for individuals diagnosed with intermediate …
Prostate
Recruiting
GUIDE
ANZUP 1903
NSW | VIC
A phase II trial of biomarker-driven intermittent docetaxel in metastatic castration-resistant prostate cancer (mCRPC)
Testicular
Recruiting
P3BEP
ANZUP 1302
NSW | VIC | QLD | SA | TAS | WA | NZ | UK | USA
Accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours: a randomised phase III trial
Bladder
In Follow-up
PCR MIB
ANZUP 1502
NSW | VIC | WA
Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer
Prostate
In Follow-up
proPSMA
HREC/16/PMCC/130
NSW | VIC | QLD | SA | WA
A prospective randomised multi-centre study of the impact of Ga-68 PSMA-PET/CT imaging for staging high risk prostate cancer prior to curative-intent surgery or radiotherapy
Kidney
In Follow-up
RAMPART
ANZUP 1606
NSW | VIC | QLD | SA
Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART): An international investigator-led phase III multi arm multi stage multi-centre randomised cont…
Prostate
In Follow-up
TheraP
ANZUP 1603
NSW | VIC | QLD | SA | WA
A randomised phase II trial of 177Lu-PSMA617 theranostic versus cabazitaxel in progressive metastatic castration resistant prostate cancer
Testicular
In Follow-up
TIGER
ANZUP 1604
NSW | VIC | QLD | International
A Randomised Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Us…
Kidney
In Follow-up
UNICAB
ANZUP 1802
NSW | VIC | QLD | SA
A Phase II Trial Of Single Agent Cabozantinib In Patients With Locally Advanced Or Metastatic Non-Clear Cell Renal Cell Carcinoma Post Immunotherapy Or Who Are Unsuitable For Immunotherapy
Kidney
In Follow-up
UNISoN
ANZUP 1602
NSW | VIC | QLD | SA | WA
UNISoN: anzUp Nivo -> Ipi + Nivo Sequential Non-clear cell Proposed phase II sequential cohort trial of single agent Nivolumab, then combination Ipil…
Prostate
Recruiting
WOMBAT
ANZUP 2201
NSW | QLD | SA
Working Out M0 Bipolar Androgen Therapy (WOMBAT)
Prostate
In Follow-up
#UpFrontPSMA
18/047
NSW | VIC | QLD | SA | WA
A Randomised Phase 2 Study of Sequential 177Lu-PSMA617 and Docetaxel Versus Docetaxel in Metastatic Hormone-Naive Prostate Cancer
Kidney
In Follow-up
FASTRACK II
TROG 15.03
NSW | VIC | QLD | SA
TROG 15.03 Focal Ablative STereotactic RAdiosurgery for Cancers of the Kidney – A Phase II Clinical Trial
Prostate
Recruiting
NINJA
TROG 18.01
NSW | VIC | QLD | SA | WA | NZ
Novel Integration of new prostate radiation therapy schedules with adjuvant androgen deprivation